This pathophysiology diagram illustrates the role of the Beta-2 Adrenergic Receptor (ADRB2) in modulating inflammatory responses during Rhinovirus (RV) infection. The visual is divided into three primary sections: [1] depicts RV particles binding to Intercellular Adhesion Molecule 1 (ICAM-1) on the surface of airway epithelial cells (ECs). [2] demonstrates that ADRB2 activation inhibits the expression of ICAM-1 and the subsequent release of cytokines and chemokines from these epithelial cells. [3] focuses on systemic immune cell modulation, showing that ADRB2 signaling exerts inhibitory effects (indicated by red T-bars) on multiple cell types: in macrophages (Mφ), it suppresses TNF-α, IL-6, IL-1β, and various CCL chemokines; in mast cells (MC), it inhibits TNF-α, histamine, and leukotriene release; in CD4+ T cells, it suppresses IFN-γ production; and in CD8+ T cells, it blocks TNF-α, IFN-γ, and cytolytic activity. The diagram serves as an educational resource for understanding neuro-immune interactions and the therapeutic mechanism of beta-agonists in dampening virus-induced airway inflammation.

In patients clinically affected by ACM, beta-blockers can prevent adrenergic arrhythmias, exercise-induced arrhythmias, and ventricular remodeling, although there are no controlled clinical trials to unequivocally demonstrate the drugs' benefit. In a cohort of well-characterized individuals with ARVC, beta-blockers were not significantly effective.183 In unaffected carriers (genotype-positive or phenotype-negative), the lack of information currently does not support long-term beta-blocker therapy. <table><thead><tr><th>COR</th><th>LOE</th><th>Recommendations</th><th>References</th></tr></thead><tbody><tr><td rowspan="2">IIb</td><td>B-NR</td><td rowspan="2">Amiodarone (LOE B-NR) and sotalol (LOE C-LD) may be reasonable in individuals with ACM for control of arrhythmic symptoms or to reduce ICD shocks.</td><td>183,207,208</td></tr><tr><td>C-LD</td></tr></tbody></table>

Recommendation Table 23. Recommendations for beta-adrenergic blocker therapy prior to cardiac surgery with cardiopulmonary bypass <table><thead><tr><th>Recommendations</th><th>Class^a</th><th>Level^b</th><th>Ref^c</th></tr></thead><tbody><tr><td>It is recommended that chronic users of beta-adrenergic blockers continue their therapy during the perioperative period of cardiac surgery with CPB to prevent postoperative arrhythmias.</td><td>I</td><td>A</td><td>[290, 294, 295]</td></tr><tr><td>Short-term, low-dose oral beta-adrenergic blocker therapy may be considered in naive patients to prevent postoperative arrhythmias in cardiac surgery with CPB.</td><td>IIb</td><td>B</td><td>[297]</td></tr></tbody></table>

A molecular pharmacology diagram illustrating the conformational switch of the Cannabinoid Receptor 2 (CB2R) between active (left) and inactive (right) states. The visual depicts a G protein-coupled receptor (GPCR) model featuring alpha-helical transmembrane domains. The central mechanism shown is the 'toggle switch' involving the Trp258 residue within a 'secondary site/toggle pocket'. On the left, the agonist HU-308 binds to the primary site, leaving Trp258 in an upright active conformation. On the right, a modified ligand stabilizes the inactive state through a stereogenic phenyl group that engages in an edge-to-face pi-interaction with Trp258, effectively 'switching off' receptor signaling. Key molecular modifications to the ligand for therapeutic development are highlighted: 1) fluorophore conjugation for imaging, 2) stereogenic phenyl group for functional inactivation (e.g., inhibiting beta-arrestin association and ERK1/2 phosphorylation), 3) azide incorporation for improved affinity, and 4) a novel resorcinol moiety. The diagram highlights structural biology concepts in drug design, specifically targeting the active/inactive equilibrium of GPCRs for pain modulation research.

Summary : This figure presents guideline recommendations for the use of beta blockers in patients with heart failure with reduced ejection fraction (HFrEF), including the class of recommendation (COR), level of evidence (LOE), and value statement. table: # Structure : • Three columns: COR, LOE, RECOMMENDATION. • COR: Green cell labeled "1". • LOE: Blue cell labeled "A". • RECOMMENDATION: Two numbered recommendations. # Recommendations : • 1. In patients with HFrEF, with current or previous symptoms, use of one of the three beta blockers proven to reduce mortality (e.g., bisoprolol, carvedilol, sustained-release metoprolol succinate) is recommended to reduce mortality and hospitalizations (references 1-3). • 2. In patients with HFrEF, with current or previous symptoms, beta-blocker therapy provides high economic value (references 4-8). # Value Statement : • "Value Statement: High Value (A)" is noted below the recommendations. # Design Encodings : • COR and LOE are color-coded: green for COR 1, blue for LOE A. • Recommendations are in black text, with references in blue. # Analysis : • The figure provides strong, high-level evidence (COR 1, LOE A) supporting the use of specific beta blockers in HFrEF for both clinical and economic benefit. • The recommendations are clear, with referenced evidence and value statement highlighted for decision-making.

<table><thead><tr><th></th><th>Propranolol</th><th>Metoprolol</th><th>Nadolol</th><th>Atenolol</th><th>Mexiletine</th><th>Quinidine</th><th>Sotalol</th></tr></thead><tbody><tr><th>Use during pregnancy</th><td>Safe</td><td>Safe</td><td>Safe</td><td>Risk</td><td>Caution</td><td>Safe</td><td>Safe</td></tr><tr><th>Use when breastfeeding</th><td>Safe</td><td>Safe</td><td>Caution</td><td>Risk</td><td>Caution</td><td>Safe</td><td>Safe</td></tr></tbody></table> Figure 2 Antiarrhythmic drug safety for commonly used drugs in pregnancy.68,69

<table> <tr> <th>Grading</th> <th>Management</th> </tr> <tr> <td>G1: Asymptomatic or mild symptoms</td> <td> Can continue ICPI.<br> Beta-blocker (eg, atenolol or propranolol) for symptomatic relief.<br> Close monitoring of thyroid function every 2-3 weeks after diagnosis to catch the transition to hypothyroidism, the most common outcome for transient subacute thyroiditis.<br> Treat transition to elevated TSH and low FT4 as for primary hypothyroidism (see 4.1.1).<br> For persistent thyrotoxicosis (&gt; 6 weeks) consider endocrine consultation for additional workup. </td> </tr> <tr> <td>G2: Moderate symptoms, able to perform ADL</td> <td> Consider holding ICPI until symptoms return to baseline.<br> Consider endocrine consultation.<br> Beta-blocker (eg, atenolol or propranolol) for symptomatic relief.<br> Hydration and supportive care.<br> For persistent thyrotoxicosis (&gt; 6 weeks) refer to endocrinology for additional workup and possible medical thyroid suppression. </td> </tr> <tr> <td>G3-4: Severe symptoms, medically significant or life-threatening consequences, unable to perform ADL</td> <td> Hold ICPI until symptoms resolve to baseline with appropriate therapy.<br> Endocrine consultation for all patients.<br> Beta-blocker (eg, atenolol or propranolol).<br> Hydration and supportive care.<br> Consider hospitalizing patients in severe cases as inpatient endocrine consultation can guide the use of additional medical therapies including steroids, SSKI, or thionamide (methimazole or propylthiouracil) and possible surgery. </td> </tr> </table> <br> (continued on following page)